Pituitary Diseases - 12 Studies Found
Withdrawn |
: Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas : Resectable, Non-functioning Pituitary Adenoma : 2010-07-28 : Drug: Farletuzumab Farletuzumab initial loading dose 5.0 mg/kg intravenous followed by 2.5 mg/kg intrave |
Completed |
: Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors :
: 2015-01-14 :
|